$89.99
A triple receptor agonist (GLP-1, GIP, and glucagon) representing one of the most advanced metabolic research peptides available.
Retatrutide (LY-3437943) is a triple agonist peptide acting simultaneously on GLP-1, GIP, and glucagon receptors. Preclinical and early clinical data suggest more pronounced effects on weight reduction and metabolic parameters than dual agonists. Nexopep supplies Retatrutide 10mg as a lyophilised research compound with third-party COA available on request. Research applications include metabolic disease modelling, obesity studies, and receptor activation profiling. For in-vitro research only.
Reviews
There are no reviews yet.